Royalty Pharma plc (RPRX)

Market Cap	15.05B
Revenue (ttm)	2.27B
Net Income (ttm)	1.15B
Shares Out	589.18M
EPS (ttm)	2.55
PE Ratio	10.00
Forward PE	6.10
Dividend	$0.84 (3.29%)
Ex-Dividend Date	Nov 15, 2024

Volume	2,019,124
Open	25.27
Previous Close	25.40
Day's Range	25.27 - 25.67
52-Week Range	24.05 - 31.66
Beta	0.46
Analysts	Strong Buy
Price Target	41.67 (+63.16%)
Earnings Date	Feb 13, 2025

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2020
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: RPRX
• Website: https://www.royaltypharma.com

Financial Performance

In 2023, Royalty Pharma's revenue was $2.35 billion, an increase of 5.24% compared to the previous year's $2.24 billion. Earnings were $1.13 billion, an increase of 2549.50%.

Analyst Forecast

According to 6 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price forecast is $41.67, which is an increase of 63.16% from the latest price.

Price Target

$41.67

(63.16% upside)

Analyst Consensus: Strong Buy